Jeffrey Wolf - Heat Biologics Chairman of the Board, CEO
Chairman
Mr. Jeffrey Alan Wolf J.D., is Chairman of the Board, Chief Executive Officer of the Company. Mr. Wolf has served our Chairman of the Board of Directors, Chief Executive Officer and President since our inception. He founded Heat Biologics in August 2008. Mr. Wolf served from June 1997 to March 2011, as managing director at SeedOne Ventures, LLC a venture firm focused on launching and growing exceptional healthcare companies from the ground up. Since founding SeedOne, Mr. Wolf has founded and run several biomedical companies. Mr. Wolfs startups include Avigen, a gene therapy company where he was a cofounder and director TyRx Pharma, a company focused on the development of biocompatible polymers where he was a cofounder and Chairman and EluSys Therapeutics, a company focused on the development of a novel technology to remove bloodborne pathogens where he was a cofounder, Chairman and Chief Executive Officer. Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics. Mr. Wolf serves as adirector of several SeedOne portfolio companies and serves as a director of Synthetic Biologics, Inc., a clinical stage company developing therapeutics to protect the gut microbiome .We selected Mr. Wolf to serve on our Board as our Chairman because he brings to the board extensive knowledge of the pharmaceutical and biotechnology industries. Having served in senior corporate positions in several biomedical companies, he has a vast knowledge of the industry and brings to the board significant executive leadership and operational experience. His business experience provides him with a broad understanding of the operational, financial and strategic issues facing public companies and his service on other public company boards provides him with extensive corporate governance knowledge. since 2008.
| Age | 54 |
| Tenure | 16 years |
| Professional Marks | MBA |
| Phone | 919 240 7133 |
| Web | https://www.heatbio.com |
Heat Biologics Management Efficiency
The company has return on total asset (ROA) of (17.1) % which means that it has lost $17.1 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (31.12) %, meaning that it created substantial loss on money invested by shareholders. Heat Biologics' management efficiency ratios could be used to measure how well Heat Biologics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 1.93 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Heat Biologics has a current ratio of 20.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Heat Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, Heat Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Heat Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Heat to invest in growth at high rates of return. When we think about Heat Biologics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 9 records | CHAIRMAN Age | ||
| Gerard Sweeney | Brandywine Realty Trust | 67 | |
| Michael Joyce | Brandywine Realty Trust | 79 | |
| Louis Camilleri | Philip Morris International | 64 | |
| James Quincey | The Coca Cola | 59 | |
| Walter DAlessio | Brandywine Realty Trust | 81 | |
| Ahmet Kent | The Coca Cola | 64 | |
| Anthony Nichols | Brandywine Realty Trust | 78 | |
| Muhtar Kent | The Coca Cola | 62 | |
| Lucio Noto | Philip Morris International | 81 | |
Management Performance
| Return On Equity | -31.12 | |||
| Return On Asset | -17.1 |
Heat Biologics Leadership Team
Elected by the shareholders, the Heat Biologics' board of directors comprises two types of representatives: Heat Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heat. The board's role is to monitor Heat Biologics' management team and ensure that shareholders' interests are well served. Heat Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heat Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Smith, Independent Director | ||
| Timothy Creech, CFO | ||
| Melissa Price, VP of Product Devel. | ||
| John Monahan, Independent Director | ||
| Louis Bock, Independent Director | ||
| Taylor Schreiber, Vice President - Research and Development | ||
| Ann Rosar, Vice President - Finance, Corporate Secretary | ||
| Paul Belsky, Independent Director | ||
| Mark Weinberg, Executive Vice President - Clinical Development | ||
| Anil Goyal, VP of Bus. Devel. | ||
| Jeff Hutchins, Chief Scientific Officer, Senior Vice President - Pre-Clinical Development | ||
| Michael Kharitonov, Independent Director | ||
| Robert Jakobs, Controller | ||
| John Prendergast, Director | ||
| Melissa Conger, IR Contact Officer | ||
| Jeffrey Wolf, Chairman of the Board, CEO | ||
| Durham NC, IR Contact Officer |
Heat Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Heat Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -31.12 | |||
| Return On Asset | -17.1 | |||
| Current Valuation | (34.74 M) | |||
| Shares Outstanding | 25.4 M | |||
| Shares Owned By Insiders | 5.20 % | |||
| Shares Owned By Institutions | 10.77 % | |||
| Number Of Shares Shorted | 1.17 M | |||
| Price To Earning | (1.29) X | |||
| Price To Book | 0.48 X | |||
| Price To Sales | 28.62 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Heat Biologics information on this page should be used as a complementary analysis to other Heat Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Heat Stock
If you are still planning to invest in Heat Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Heat Biologics' history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |